Novavax Wins $179 Million Contract

The U. S. government awarded Novavax Inc. (Nasdaq: NVAX) a contract valued at up to $179 million to develop pandemic and seasonal recombinant flu vaccines. Novavax also licensed its proprietary recombinant virus-like-paricle vaccine technology to LG Life Sciences to develop and commericialize vaccines in South Korea. The stock price climbed 36 cents to close at $2.96.